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This review identifies understudied areas of emerging contaminant (EC) research in waste-
waters and the environment, and recommends direction for future monitoring. Non-
regulated trace organic ECs including pharmaceuticals, illicit drugs and personal care
products are focused on due to ongoing policy initiatives and the expectant broadening of
environmental legislation. These ECs are ubiquitous in the aquatic environment, mainly
derived from the discharge of municipal wastewater effluents. Their presence is of concern
due to the possible ecological impact (e.g., endocrine disruption) to biota within the envi-
ronment. To better understand their fate in wastewaters and in the environment, a stand-
ardised approach to sampling is needed. This ensures representative data is attained and
facilitates a better understanding of spatial and temporal trends of EC occurrence. During
wastewater treatment, there is a lack of suspendedparticulatematter analysis due to further
preparation requirements and a lack of good analytical approaches. This results in the
under-reporting of several ECs entering wastewater treatment works (WwTWs) and the
aquatic environment. Also, sludge can act as a concentrating medium for some chemicals
during wastewater treatment. The majority of treated sludge is applied directly to agricul-
tural landwithout analysis for ECs. As a result there is a paucity of information on the fate of
ECs in soils and consequently, there has been no driver to investigate the toxicity to exposed
terrestrial organisms. Therefore a more holistic approach to environmental monitoring is
required, such that the fate and impact of ECs in all exposed environmental compartments
are studied. The traditional analytical approach of applying targeted screening with low
resolution mass spectrometry (e.g., triple quadrupoles) results in numerous chemicals such
as transformationproducts goingundetected. These canexhibit similar toxicity to theparent
EC, demonstrating the necessity of using an integrated analytical approach which compli-
ments targeted and non-targeted screening with biological assays to measure ecological
impact. With respect to current toxicity testing protocols, failure to consider the enantio-
meric distribution of chiral compounds found in the environment, and the possible toxico-
logical differences between enantiomers is concerning. Such information is essential for the
development of more accurate environmental risk assessment.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/3.0/).013; fax: þ44 (0)1225 386231.
.ac.uk (B. Kasprzyk-Hordern).
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contaminants are controlled by legislation outlined by the
European Commission (European Commission, 2008). These
have traditionally been industrial or agricultural chemicals.
However, legislation is expected to broaden to encompass a
greater number of municipal derived chemicals described as
ECs following the recent proposal of the pharmaceuticals
17b-estradiol (E2), 17a-ethinylestradiol (EE2) and diclofenac as
priority hazardous substances (European Commission, 2012).
Proposed legislative targets for consent were 0.4, 0.035 and
100 ng l1 for E2, EE2 and diclofenac, respectively (European
Commission, 2012). Also, dissemination of antibiotic resis-
tant bacteria in the environment caused by the presence of
antibacterial drugs is an emerging concern (Marti et al., 2014).
This emphasises the level of concern posed by this family of
environmental pollutants. Large numbers of non-regulated
ECs have been observed mainly in the ng to mg l1 range in
surface waters throughout the UK (Ashton et al., 2004;
Roberts and Thomas, 2006; Kasprzyk-Hordern et al., 2007,
2008a,b, 2009; Baker and Kasprzyk-Hordern, 2011a, 2013) and
across the rest of Europe (Gracia-Lor et al., 2011; Gros et al.,
2012; Kunkel and Radke, 2012; Ferrando-Climent et al., 2013;
Fenech et al., 2013; Hughes et al., 2013; Loos et al., 2013;
Lopez-Serna et al., 2013). To date, >200 different pharma-
ceuticals alone have been reported in river waters globally,
with concentrations up to a maximum of 6.5 mg l1 for the
antibiotic ciprofloxacin (Hughes et al., 2013). Single com-
pound acute toxicity testing (including crustaceans, algae
and bacteria) conducted under controlled laboratory condi-
tions have found median effective concentrations (EC50's e
concentration at which the toxicological response to an or-
ganism is halfway between a normal and maximum
response for a pre-set time period) for a number of these ECs
to be < 1 mg l1 (Bruce and Versteeg, 1992; Holten Lu¨tzhøft
et al., 1999; Halling-Sørensen, 2000; Brooks et al., 2003;
Andreozzi et al., 2004; Brain et al., 2004; Eguchi et al., 2004;
Cleuvers, 2005; Isidori et al., 2005a,b; DellaGreca et al., 2007;
Isidori et al., 2007; DeLorenzo and Fleming, 2008; Terasaki
et al., 2009; Giudice and Young, 2010). Such effect concen-
trations classify the chemical as potentially very toxic to
aquatic organisms as described under the EU-Directive 93/67/
EEC (Commission of the European Communities, 1996;
Cleuvers, 2003). The presence of these chemicals in the
environment is more concerning considering that they do not
appear individually, but as a complex mixture, which could
lead to unwanted synergistic effects. The ubiquity of a high
number of potentially toxic ECs in the environment un-
derpins the need to better understand their occurrence, fate
and ecological impact.
This review describes current knowledge on the occur-
rence of ECs in wastewaters and surface waters using the UK
data set as an example. From the data set andwider literature,
areas of concern considered to be understudied are discussed.
Among them are: spatial and temporal variability of ECs in
wastewater and river water, partitioning of ECs to solidmatter
during wastewater treatment, fate of ECs in environmental
waters and toxicological impact of ECs within theenvironment. Finally, recommendation for future environ-
mental monitoring approaches is proposed.2. Current knowledge of EC occurrence in
wastewaters and surface waters
The presence of ECs in the environment is mainly attributed
to the discharge of treated wastewater from WwTWs. Con-
ventional secondary processes (activated sludge and trickling
filters) represent the most extensively used and studied pro-
cesses and are therefore focused on in this review. However,
these processes are not designed to remove ECs resulting in
their discharge to receiving surface waters including rivers,
lakes and coastal waters. A UK data set is used as a baseline to
outline current knowledge of EC contamination within
wastewaters and surface waters for a European country.
Approximately 70 pharmaceuticals belonging to a variety
of therapeutic classes have been reported in UK environ-
mental waters (Table 1). The most studied are non-steroidal
anti-inflammatory drugs (NSAIDs), b-blockers, anti-
depressants and the antiepileptic carbamazepine. These are
highly prescribed (>1000 kg per annum) and ubiquitous to
influentwastewaters. Removal varies broadly from low (<50%)
to high (>80%) due to their different physicochemical prop-
erties and susceptibility to biological attack (Tadkaew et al.,
2011; Petrie et al., 2013a). Incomplete removal results in
pharmaceuticals being reported in receiving surface waters in
the ng to mg l1 range. The analgesic tramadol has been
observed in river water at the highest concentration up to a
maximum of 7731 ng l1 (Kasprzyk-Hordern et al., 2008b). To
date, a total of 15 illicit drugs and licit stimulants have been
reported in UK wastewaters (Table 1). Due to the lower con-
sumption of illicit drugs within the community, concentra-
tions observed in influent wastewaters are expectantly lower.
Nevertheless, incomplete removal during wastewater treat-
ment has resulted in several of these ECs being found in final
effluents and receiving surface waters. The hallucinogen 3,4-
methylenedioxy-N-methylamphetamine (MDMA) and the
stimulant cocaine have been observed in river water at con-
centrations of 25 and 17 ng l1, respectively (Baker and
Kasprzyk-Hordern, 2011a,b, 2013). In contrast, antimicro-
bials, sunscreen agents and preservatives are high usage
chemicals due to their application in a broad range of personal
care products. These types of chemical are often observed in
influent wastewater at >1000 ng l1 (Table 1). Removals during
wastewater treatment are generally good and range from 50 to
100%. However, notable concentrations remain in final efflu-
ents owing to the relatively high influent concentrations
encountered. The sunscreen agent 4-benzophenone has been
observed at mean final effluent concentrations ranging from
3597 to 5790 ng l1 (Kasprzyk-Hordern et al., 2008a, 2009). The
data set also revealed that the majority of EC analysis is un-
dertaken on the aqueous phase (i.e., a pre-filtered sample)
only, and there has been a lack of particulate phase mea-
surements made (e.g., sludge or suspended particulate mat-
ter). The observations of the UK data set are typical of EC
research reported throughout the rest of Europe (Gracia-Lor
et al., 2011; Gros et al., 2012; Ferrando-Climent et al., 2013;
Table 1 e Emerging contaminant occurrence information for wastewaters and surface waters in the UK (all data reported as mean concentrations and aqueous phases
unless otherwise stated).
Emerging
contaminant
Family/use Prescription
2012 (kg)a
Excretion
unchanged (%)
Known metabolites Influent
(ng l1)
Removal
(%)
Sludge
(ng kg1)
Final
effluent
(ng l1)
Surface
water
(ng l1)
Surface water
max. (ng l1)
Pharmaceuticals
Estrone Steroid estrogen e e Sulfate and glucuronide
conjugates
49c L-Hc,m e 4.3e12b,m e e
17b-estradiol Steroid estrogen 84 e Sulfate and glucuronide
conjugates
20c M-Hc,m e 0.4e1.3b,m e e
17a-ethinylestradiol Synthetic estrogen 12 e Sulfate and glucuronide
conjugates
1.0c L-Hc,m e 0.20e0.47b,m e e
Propranolol Beta blocker 9076 <0.5d 4-Hydroxypropranolol
(active),
glucuronide conjugates
(20%)f
60e638c,e,g,j L-Hc,g,j 170c 93e388b,e,g,j,k <0.5e107deg,j,k 215k
Metoprolol Beta blocker 2311 10e30d No active metabolitesf 75e110e,g L-Mg e 41e69e,g <0.5e10deg 12f
Sulbutamol Beta blocker 182 30d Sulfate conjugate 0.1e130e,g M-Hg e 63e66e,g <0.5-2eeg 8f
Atenolol Beta blocker 20,725 50d Hydroxylated
metabolite (3%)f
12,913e14,223e,g M-Hg e 2123e2,870e,g <1e487deg 560f
Carbamazepine Antiepileptic 44,498 3d Hydroxylated
(10,11-epoxide)
(active), conjugated
metabolitesf
950e2,593e,g Lg 826e3,117e,g <0.5e251deg 684f
Gabapentin Antiepileptic 104,110 100d e 15,034e18,474e,g L-Hg 2592e21,417e,g <0.6e1,879deg 1,887f
Acetaminophen NSAID >2,000,000 20d Sulfate conjugate (30%),
paracetmaol
cysteinate,
mercapturate (5%)f
6924e492,340e,g,j Hg,j e <20e11,733e,g,j <1.5e1,388deg 2,382f
Diclofenac NSAID 10,652 5e10f Glucuronide,
sulfate conjugatesf
69e1,500c,e,g,j L-Hc,g,j 70c 58e599b,e,g,j,k <0.5e154eeg,k 568k
Ibuprofen NSAID 108,435 1f (þ)-2-40-(2-Hydroxy-2-
methylpropyl)-
phenylpropionic
acid (25%) and
(þ)-2-40-(2-carboxypropyl)-
phenylpropionic
acid (37%),
conjugated
ibuprofen (14%)f
1681e33,764c,e,g,j Hc,g 380c 143e4,239b,e,g,j,k 1e2,370eeg,j,k 5,044k
Naproxen NSAID 126,258 <1 6-o-Desmethyl
naproxen (<1%),
conjugates (66e92%)f
838e1,173g Mg e 170e370g 1e59f,g 146f
Ketoprofen NSAID 243 0e50 2-(3-benzoylphenyl)-
propanoic acid and
glucuronides
28e102e,g Mg e 16e23e,g 1e4eeg 14f
Clofibric acid Metabolite e e e 1e651e,g,j L-Hg,j e 6e44e,g,j <0.3e101eeg 164f
Salicylic acid Metabolite e e e 5866e52,000c,e,g L-Hc,g e 75e209e 4e62eeg 302f
(continued on next page)
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Table 1 e (continued )
Emerging
contaminant
Family/use Prescription
2012 (kg)a
Excretion
unchanged (%)
Known metabolites Influent
(ng l1)
Removal
(%)
Sludge
(ng kg1)
Final
effluent
(ng l1)
Surface
water
(ng l1)
Surface water
max. (ng l1)
Ranitidine H2 receptor
agonist
35,665 30d N-oxide (3e6%),
S-oxide (1e2%)
desmethyl
ranitidine (1e2%)f
<12e5,060e,g L-Hg e <9e425e,g <3e32deg 73f
Cimetidine H2 receptor
agonist
3195 48e75d Cimetidine
N-glucuronide (24%),
cimetidine
suphoxide (7e14%),
hydroxymethylcimetidine
(4%)f
2219e3,452e,g L-Mg e 462e2,605e,g <0.5e105eeg 220f
Furosemide Diuretic 14,840 Littlef Mainly glucuronidesf 1476e2,789e,g L-Mg e 629e1,161e,g <6e129eeg 630f
Bezafibrate Lipid regulator 7966 50f Glucuronides (20%)f 420e971e,g L-Mg e 177e418e,g <10e60eeg 90g
Simvastatin Lipid regulator 49,198 Little b-Hydroxyacid metabolitef <7e115e,g e e <3e5e,g <0.6d,e,g e
Fluoxetine Antidepressant 5319 11l Norfluoxetine 14e86c,h,i,l L-Hc,i 170c 16e29b,h,i 5.8e14h,i 14h,i
Norfluoxetine Metabolite e e e 3.3e63h,i,l Mi e 5.8e13h,i 1.3e2.8h,i 3.5i
Venlafaxine Antidepressant 16,211 5l Desmethylvenlafaxine 120e249h,i,l Li e 95e188h,i 1.1e35h,i 85i
Dosulepin Antidepressant 3270 11l Desmethyldosulepin 21e228h,i,l M-Hi e 57h 0.5e25h,i 32h,i
Amitriptyline Antidepressant 10,171 2l Nortriptyline,
10-hydroxyamitriptyline
(active),
10-Hydroxynortriptyline
(active)f
106e2,092e,g,h,i,l M-Hg,i e 66e207eei <0.5e30dei 72h
Nortriptyline Antidepressant 439 3l Hydroxynortriptyline 5.1e114h,i,l Mi e 7.6e33h,i 0.8e6.8h,i 19h,i
Valsartan Hypertension 6484 80d Valeryl 4-hydroxy valsartanf 342e1,734e,g L-Hg e 192e344e,g <1e55deg 144f
Diltiazem Calcium-channel
blocker
21,922 2e4f Desacetyldiltiazem,
N-monodemethyldiltiazem
(active)f
770e1,559e,g L-Mg e 95e357e,g <1e17deg 65f
Theophylline Bronchodilator 4l 10 Caffeine, 3-methylxanthine 9467e20,400h,i,l Hi e 1220e3,169h,i 76e558h,i 1,439i
Tramadol Analgesic 41,445 15e35d,l Desmethyltramadol
(active)f
733e48,488eei,l Lg,i e 739e59,046e,g,h,i <30e5,970def,h,i 7,731f
Nortramadol Metabolite e e e 226e2,457h,i,l M-Hi e 145e433h,i 11e181h,i 410i
Codeine Various 34,626 64e70d,l Codeine-6-glucuronide
(main),
free/conjugated morphine
(10e15%), norcodeine
(10e20%)f
1088e10,321eei,l L-Hg,i e 372e5,271e,gei <1.5e347dei 815f
Norcodeine Metabolite e e e 30e112h,i,l Mi e 24e33h,i 2.1e9.0h,i 20h
Oxycocodone Analgesic e 9l Noroxycocodone,
oxymorphone,
5.0e12h,i,l Li e 7e12h,i 0.5e3h,i 7.1h
Oxymorphone Analgesic e 11l Noroxycodone,
noroxymorphone
11e20h,i,l e e <1.7e8.4h,i <0.1e2.3h,i 3.5i
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Morphine Analgesic 5684 55l Morphine-3-glucuronide,
morphine-6-glucuronide,
normorphine
340e481h,i,l Hi e 59e131h,i 1.6e36h,i 36h
Normorphine Metabolite e e e 51e203h,i,l Hi e 20e62h,i <5e5.7h,i 5.7i
Dihydrocodeine Analgesic 9720 54l Dihydromorphine
(active)
227e386h,i,l Li e 118e146h,i 2.9e36h,i 97i
Buprenorphine Various 91 1l Norbuprenorphine and
glucuronides
33e47h,i e e 14h <0.5e15h,i 14i
Norbuprenorphine Metabolite e e e <1e19h,i e e <0.7e7.5h,i <0.5e12.2h,i 3.4i
Methadone Analgesic 1687 28l EDDP, EMDP 52e88h,i,l Li e 42e50h,i 0.6e12h,i 24i
EDDP Metabolite e e e 71e193h,i,l L-Mi e 32e89h,i 1.2e19h,i 38h
EMDP Metabolite e e e 1.8e5.7h,i e e 1.3e1.7h,i 0.6e1.0h,i 1.1h
Fentanyl Analgesic 1.0 3l Norfentanyl,
despropionylfentanyl
1.3e1.7h,i e e <0.1e0.5h,i <0.1h e
Norfentanyl Metabolite e e e 6.9h e e 1.1h <0.1h e
Propoxyphene Analgesic e 1l Norproxyphene 8.2e11h,i e e 7.1h <0.1h e
Norpropoxyphene Metabolite e e e <4.2e184h,i,l Li e 91e106h,i 6.5e31h,i 80i
Temazepam Hypnotic 833 75l Oxazepam 85e208h,i,l Li e 135e179h,i 3.2e34h,i 78i
Diazepam Hypnotic 335 Tracel Nordiazepam,
temazepam,
oxazepam
<0.9e7.6h,i e e 1.6e5.1h,i 0.6e0.9h,i 1.1h,i
Nordiazepam Metabolite e e e 12e25h,i,l Mi e 5.8e9.9h,i 0.7e3.2h,i 6.8i
7-Aminonitrazepam Metabolite e e e <1.9e205h,i e e <1.2h <0.5h e
Oxazepam Hypnotic 85 33l Glucuronide metabolite 22e50h,i,l Li e 33e58h,i 2.4e11h,i 21i
Ketamine Anaesthetic 64 2l Norketamine 52e235h,i,l Li e 83e130h,i 0.6e27h,i 54i
Norketamine Metabolite e e e 11e85h,i,l Li e 14e28h,i 1.7e5.8h,i 14h
Sildenafil Erectile
dysfunction
570 <1 N-desmethyl sildenafil 8.3e25h,i,l Li 7.0e9.7h,i <1e2.2h,i 2.9i
Ephedrine/
pseudoephedrine
Various 622 40e90 Cathine 476e966h,i,l Hi e 35e70h,i 7.7e15h,i 17e29h,i
Norephedrine Various e 80e90 e 40e86h,i Hi e 59h <5h e
Amoxicillin Antibacterial 158,231 30e70 Amoxicilloic acid <87e e e 31e <2.5e245d,e,f 622f
Erythromycin Antibacterial 41,057 5d Erythromycin-H2O
f 71e2,530c,e,g,j L-Hc,g,j 50c 109e1,385b,e,g,j,k <0.5e159deg,j,k 1,022k
Metronidazole Antibacterial 12,300 20d 1-(b-hydroxymethyl-
5-nitroimidazole,
2-methyl-5-
nitroimidazole-1yl-
acetic
acidf
569e2,608e,g Lg e 265e373e,g <1.5e12deg 24f
Ofloxacin Antibacterial 219 65e80 Desmethyl, N-oxide
metabolites
180c M-Hc 210c 10b e e
Chloramphenicol Antibacterial e 8e12d Glucuronide
conjugatesf
<4e248e,g Hg e <6e21e,g <10d,f,g 40f
Sulfamethoxazole Antibacterial e 30d N4-acetylated
metabolite
<3e115e,g L-Mg e 10e19e,g <0.5e2deg 8g
Sulfapyridine Antibacterial e <10 Hydroxyl, acetyl
metabolites
914e4,971g L-Hg e 277e455g <2e28f,g 142f
(continued on next page)
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Table 1 e (continued )
Emerging
contaminant
Family/use Prescription
2012 (kg)a
Excretion
unchanged (%)
Known metabolites Influent
(ng l1)
Removal
(%)
Slud
(ng kg
Final
effluent
(ng l1)
Surface
water
(ng l1)
Surface water
max. (ng l1)
Sulfasalazine Chronic
bowel
disorders
54,039 15 5-Aminosalicylic acid
(active),
sulfapyridine (active)f
0.2e116e,g Lg e 0.3e484e,g <1.5e76eeg 168f
Trimethoprim Antibacterial 10,998 80d 1,3-oxides, 30 4-hydroxy
derivativesf
213e2,925e,g,j L-Mj,g e 128e1,152e,g,j,k <1.5e108deg,j,k 183f
Oxytetracycline Antibacterial 17,143 30 N-desmethyloxytetracycline 3600 Hc 6710 170b e e
Tamoxifen Anti-cancer 453 30 Hydroxytamoxifen (active) 143e215j Lj e <10e369j,k <10e212j,k e
Illicit drugs and licit stimulants
MDMA Hallucinogen e 20l MDA, HMMA, HMA 10e231h,i,l Li 13e38h,i 0.5e8.7h,i 25h,i
MDEA Hallucinogen e 19l MDA <0.3e1.4h,i e e <0.5h <0.1h e
MDA Hallucinogen/
metabolite
e Highl e 10e18h,i,l e e 11e15h,i <0.1e1.7h,i 1.7i
Amphetamine Stimulant e 1e74d,l 25% Phenylacetone,
benzoic acid,
hippuric acid, <10%
4-hydroxy-norephedrine,
norephedrinef
77e5,236eei,l Hg,i e 2e201e,gei <1e9dei 4.3h
Methamphetamine Stimulant e 43l Amphetamine,
4-hydroxymethamphetamine
2e40h,i,l M-Hi e 0.8e1h,i <0.1e0.3h,i 0.3i
Cocaine Stimulant e 1e9f,l 35e54% benzoylecgonine,
32e49% ecgoninef
methyl ester (main)
57e526e,gei,l L-Hi e <1e149e,gei <0.3e6dei 17i
Benzoylecgonine Metabolite e e e 196e1,544e,gei,l L-Hg e 13e1,597e,gei <1e92dei 72i
Norbenzoylecgonine Metabolite e 1l e 6e54h,i,l e e 3.6e7h,i 0.3e2h,i 3.1i
Norcocaine Metabolite e e e 1h e e <0.2h 0.1h 0.1h
Cocaethylene Metabolite e e e 3e45h,i,l L-Mi e 1.7e3.8h,i 0.1e0.6h,i 1.4h
Benzylpiperazine Stimulant e 7(rat)l Hydroxylated metabolite 22e25h,i L-Hi e 31e44h,i 1.1e26h,i 65h
Trifluoromethyl-
phenylpiperazine
Stimulant e <1(rat)l Hydroxylated metabolite 2.4e5.1h,i,l e e 4.6e6.6h,i 0.2e1.2h,i 6.1i
6-acetylmorphine Metabolite e <1l e 3.0e22h,i,l e e <0.3e2.2h,i <0.1h e
Caffeine Human indicator e 1l Acids and 1-methylxanthine 9902e25,138h,i,l Hi e 1744e2,048h,i 163e743h,i 1,716i
Nicotine Human indicator 442 e e 3919e9,684h,i,l Hi e 52h 12e86h,i 148i
Personal care products
Triclosan Antibacterial e e e 70e2,500c,e,g M-Hc,g 5,14 25e200b,e,g 5e48eeg e
Bisphenol A Plasticizer e e e 416e2,050c,e,g M-Hc,g 320c 35e86b,e,g <6e34eeg e
1-benzophenone Sunscreen agent e e e 134e306e,g Hg e 12e32e,g <0.3e9e,f e
2-benzophenone Sunscreen agent e e e 25e194e,g Hg e 1e4e,g <0.5e18eeg e
3-benzophenone Sunscreen agent e e e 638e1,195e,g M-Hg e 22e231e,g <15e36eeg e
4-benzophenone Sunscreen agent e e e 3597e5,790e,g Lg e 2701e4,309e,g <3e227eeg e
Methylparaben Preservative e e e 2642e11,601e,g Hg e <3e50e,g <0.3e68eeg e
Ethylparaben Preservative e e e 589e2,002e,g Hg e 4e50e,g 1e13eeg e
Propylparaben Preservative e e e 598e3,090e,g Hg e 26e63e,g <0.2e7eeg e
Butylparaben Preservative e e e 50e723e,g Hg e <1e,g <0.3e6eeg e
w
a
t
e
r
r
e
s
e
a
r
c
h
7
2
(2
0
1
5
)
3
e
2
7
8ge
1)
0c
K
e
y
:
N
S
A
ID
,
n
o
n
-s
te
ro
id
a
l
a
n
ti
-i
n
fl
a
m
m
a
to
ry
d
ru
g
;
L
,
se
co
n
d
a
ry
re
m
o
v
a
l
is
<
5
0
%
;
M
,
se
co
n
d
a
ry
re
m
o
v
a
l
is
w
it
h
in
th
e
ra
n
g
e
5
0
e
8
0
%
;
H
se
co
n
d
a
ry
re
m
o
v
a
l
>
8
0
%
.
a
T
a
k
e
n
fr
o
m
N
H
S
P
re
sc
ri
p
ti
o
n
C
o
st
A
n
a
ly
si
s
in
fo
rm
a
ti
o
n
fo
r
E
n
g
la
n
d
(N
a
ti
o
n
a
l
H
e
a
lt
h
S
e
rv
ic
e
,
2
0
1
2
).
b
M
e
d
ia
n
d
a
ta
re
p
o
rt
e
d
fr
o
m
1
6
2
W
w
T
W
s
e
G
a
rd
n
e
r
e
t
a
l.
,
2
0
1
2
.
c
D
a
ta
o
b
ta
in
e
d
fr
o
m
1
4
W
w
T
W
s
(i
n
c.
a
ct
iv
a
te
d
sl
u
d
g
e
,
tr
ic
k
li
n
g
fi
lt
e
rs
,
m
e
m
b
ra
n
e
b
io
re
a
ct
o
rs
a
n
d
b
io
lo
g
ic
a
l
n
u
tr
ie
n
t
re
m
o
v
a
l
p
la
n
ts
e
G
a
rd
n
e
r
e
t
a
l.
,
2
0
1
3
.
d
K
a
sp
rz
y
k
-H
o
rd
e
rn
e
t
a
l.
,
2
0
0
7
.
e
K
a
sp
rz
y
k
-H
o
rd
e
rn
e
t
a
l.
,
2
0
0
8
a
.
f
K
a
sp
rz
y
k
-H
o
rd
e
rn
e
t
a
l.
,
2
0
0
8
b
.
g
T
w
o
W
w
T
W
s
m
o
n
it
o
re
d
(a
ct
iv
a
te
d
sl
u
d
g
e
a
n
d
tr
ic
k
li
n
g
fi
lt
e
r)
K
a
sp
rz
y
k
-H
o
rd
e
rn
e
t
a
l.
,
2
0
0
9
.
h
B
a
k
e
r
a
n
d
K
a
sp
rz
y
k
-H
o
rd
e
rn
,
2
0
1
1
a
.
i
S
e
v
e
n
W
w
T
W
s
(a
ct
iv
a
te
d
sl
u
d
g
e
a
n
d
tr
ic
k
li
n
g
fi
lt
e
rs
),
m
e
d
ia
n
d
a
ta
re
p
o
rt
e
d
e
B
a
k
e
r
a
n
d
K
a
sp
rz
y
k
-H
o
rd
e
rn
,
2
0
1
3
.
j
W
w
T
W
s
is
a
tr
a
in
o
f
p
ro
ce
ss
e
s
(t
ri
ck
li
n
g
fi
lt
e
r,
a
ct
iv
a
te
d
sl
u
d
g
e
a
n
d
U
V
tr
e
a
tm
e
n
t)
R
o
b
e
rt
s
a
n
d
T
h
o
m
a
s,
2
0
0
6
.
k
F
iv
e
W
w
T
W
s
(o
x
id
a
ti
o
n
d
it
ch
,
a
ct
iv
a
te
d
sl
u
d
g
e
a
n
d
tr
ic
k
li
n
g
fi
lt
e
rs
)
A
sh
to
n
e
t
a
l.
,
2
0
0
4
.
l
B
a
k
e
r
e
t
a
l.
,
2
0
1
4
.
m
In
cl
u
d
e
s
p
a
rt
ic
u
la
te
co
n
ce
n
tr
a
ti
o
n
s
e
K
o
h
e
t
a
l.
,
2
0
0
9
.
wa t e r r e s e a r c h 7 2 ( 2 0 1 5 ) 3e2 7 9Fenech et al., 2013; Hughes et al., 2013; Loos et al., 2013; Lopez-
Serna et al., 2013).3. Understudied areas of EC pollution in
wastewaters and the environment
The data set described (Table 1), and wider literature was used
to identify key areas of concern considered to be under-
studied. These are discussed to address deficiencies in current
knowledge of EC contamination in wastewaters and the
environment.
3.1. Spatial and temporal variability of ECs in
wastewater and river water
3.1.1. Factors which influence receiving wastewater
concentration
A large variation in influent wastewater concentrations
(equivalent to more than an order of magnitude) has been
observed for some ECs (Table 1). For example, acetaminophen
was found within influent wastewater at mean concentra-
tions ranging from6924 to 492,340 ng l1 (Roberts and Thomas,
2006; Kasprzyk-Hordern et al., 2008a, 2009) (Table 1). This in-
dicates spatial and/or temporal variations in their usage.
However dilution from industrial inputs, degradation within
the upstream sewer, rainfall and sampling mode will all
contribute to this variability. The use of inappropriate sam-
pling strategies is considered the greatest weakness of re-
ported occurrence data. Ort et al. (2010a,b) gave an excellent
account of uncertainties associated with different sampling
modes. Current approaches tend to use discrete grab sampling
of low inter-day frequency and often no intra-day repetition.
To demonstrate, all reported data in Table 1 was obtained
using a grab sampling approach. This approach has limita-
tions as it only yields a snap shot of EC concentration for a
specific point in time. Time and volume/flow proportional
composite samplers are also used (Plosz et al., 2010; Coutu
et al., 2013; Lopez-Serna et al., 2013), but to a lesser extent.
The latter being preferred as it accounts for fluctuations in
flow. The relatively high cost and logistical issues associated
with this sampling mode has resulted in very few studies
applying flow proportional sampling. Also, a major uncer-
tainty of 24 h composite sampling is chemical stability. This is
not often investigated but is known to be significant for some
chemicals (Baker and Kasprzyk-Hordern, 2013). Due to un-
certainties of existing sampling methods, there is lack of un-
derstanding on spatial and temporal variations in EC
concentrations.
3.1.2. Spatial distribution
Assessing spatial distribution of EC contamination is notori-
ously difficult. The collation and interpretation of literature
data from a variety of sources has obvious limitations. On the
other hand, studies have been able to tentatively assess
spatial distribution within a single catchment (Vazquez-Roig
et al., 2012; Baker and Kasprzyk-Hordern, 2013). Such studies
have to rely heavily on discrete grab sampling due to the large
number of sites which are monitored at approximately the
same time. Despite the uncertainties associated with grab
Fig. 1 e Fluctuations of mass flux for selected antibiotics in wastewater throughout a one day period (a) and during the
course of a year (b) e adapted from Coutu et al. (2013).
wat e r r e s e a r c h 7 2 ( 2 0 1 5 ) 3e2 710sampling, information attained from such studies is
extremely valuable. It can be used as a primary indicator of
sites within the catchment that require more detailed study.
These can then be subject to more robust sampling protocols
to facilitate greater understanding of EC fate and occurrence
duringwastewater treatment and in the environment at these
predetermined sites of interest.
3.1.3. Intra-day variation
It is anticipated that concentrations of ECs in receiving
wastewater vary throughout the day. Coutu et al. (2013)
collected hourly composite samples (i.e., one sample every
15 min to create an hourly composite) for influent wastewater
over 24 h sampling periods. This was used to investigate
within day variability of antibiotic concentrations. Samples
were chilled upon collection but their stability at 4 C was not
investigated or referenced to. However, significant degrada-
tion (>15%) has been observed for some ECs stored at 4 C for
only 12 h (Baker and Kasprzyk-Hordern, 2013). Despite this
uncertainty, the six antibiotics studied (trimethoprim, nor-
floxacin, ciprofloxacin, ofloxacin, clindamycin, metronida-
zole) showed variation in concentration throughout the dayFig. 2 e Inter-day variation in cocaine (COC) and MDMA consum
wastewater of 19 cities e adapted from Thomas et al. (2012).(Coutu et al., 2013). A peak in receiving load was observed
between 07:00 and 9:00 h (Fig. 1a). This is explainable by
posology and the accumulation of administered drugs within
urine during sleep (Plosz et al., 2010; Coutu et al., 2013).
Therefore following the first toilet flush of the day an increase
in load of antibiotics is observed. Other urine derived ECs are
expected to behave in the same way. Yet it is unknown how
the performance of WwTWs responds to this daily spike in
receiving concentration and volumetric load. Collection of
corresponding final effluent samples would help address this.
3.1.4. Inter-day variability
A European wide study of 19 European countries using a va-
riety of time, flow and volume proportional sampling
attempted to investigate inter-day variability (i.e., over a one
week period) of illicit drugs in influent wastewater (Thomas
et al., 2012). Collated data revealed a trend of recreational
use for some compounds (Fig. 2). Both benzoylecgonine (the
major metabolite of cocaine) and MDMA showed elevated
levels at weekends. In contrast, it is anticipated that hospital
dispensed chemicals such as X-ray contrast media and anti-
cancer drugs will be observed at higher concentrationsption calculated from a European wide study profiling
wa t e r r e s e a r c h 7 2 ( 2 0 1 5 ) 3e2 7 11during weekdays when hospital appointments are greatest.
Inter-day variability of EC concentration is difficult to fully
appreciate without conducting flow proportional sampling.
This is most significant when comparing weekday and
weekend periods where wastewater flows can vary notably.
Differences in weekday/weekend flow will be specific for the
catchment in question. For example, a residential (commuter)
or tourist area will see increased flow during weekends. On
the other hand, a catchment containing industrial works may
observe a reduction in flow and dilution during weekends.
Rainfall will also result in changes to wastewater flow be-
tween days. This illustrates that reporting load (mass per day)
over the traditional approach of concentration (mass per litre)
to overcome temporal variations in flow is more suited to
describe findings.
3.1.5. Seasonality
Some ECs have seasonal uses indicating that their influent
load will vary throughout the year. For example, monthly
prescription information for the UK showed antihistamines
used to treat allergies (e.g., hay fever) peaked from May to
August when pollen production is greatest (Fig. 3) (National
Health Service, 2012). Generally, quantities prescribed were
100% greater in summer compared to winter months. This
relationship has been established for the antihistamine
cetirizine in Norwegian wastewater (Harman et al., 2011).Fig. 3 e Monthly National Health Service Prescription Cost Ana
appliance contractors in England) for antihistamines (loratadine
(a), sunscreen and sunscreening preparations (b), pseudoephed
Health Service, 2012).Prescription information also showed a similar trend for the
number of prescribed sunscreens and sunscreening prepara-
tions (Fig. 3). This indicates that personal care products
associated with these preparations such as UV filters will also
be more prevalent in wastewater during summer. In contrast,
pseudoephedrine (used in nasal decongestants) and pholco-
dine (used in cough preparations) showed an opposite trend in
their usage with highest prescription observed during winter
months (Fig. 1) (National Health Service, 2012). Cumulative
concentration of ephedrines has been reported at higher
concentrations during winter months (Kasprzyk-Hordern and
Baker, 2012a). Furthermore, a high contribution of the enan-
tiomer 1S,2S(þ)-pseudoephedrine during winter is consistent
with increased usage of over-the-counter-medication used to
treat symptoms of cold (Kasprzyk-Hordern and Baker, 2012b).
A study by Veach and Bernot (2011) attempted to determine
temporal variations of 15 ECswithin two rivers over a one year
period. However, the sampling protocol consisted of a single
monthly grab sample which severely restricts understanding
of seasonal variation. A more robust approach which under-
took weekly 24 h flow proportional sampling every month for
a one year period, investigated temporal variations of antibi-
otics within influent wastewater (Coutu et al., 2013). Season-
ality was reported for both ciprofloxacin and norfloxacin in
receiving wastewater for a WwTW in Switzerland (Fig. 1b).
Mass fluxes were higher in winter and spring months,lysis information (items dispensed by pharmacy and
, cetirizine hydrochloride and fexofenadine hydrochloride)
rine hydrochloride (c) and pholcodine (d) in 2012 (National
wat e r r e s e a r c h 7 2 ( 2 0 1 5 ) 3e2 712explained by seasonal therapeutic use. For example, cipro-
floxacin is used to treat airway infections and infections
affecting the throat, nose and ear (Coutu et al., 2013). This
relationship could not be established for UK Prescription Cost
Analysis data (National Health Service, 2012).
3.1.6. Occasional events
There is a lack of knowledge on the impact of occasional
events to the loading of ECs in wastewater, or their impact to
wastewater treatment performance and to biota of the
receiving environment. An increase in drug use may be
anticipated during music festivals (Lai et al., 2013a), public
holidays (Lai et al., 2013b), major sporting events (Gerrity et al.,
2011) and by students during exam periods for improved
concentration (Dennhardt and Murphy, 2013). A less predic-
tive source of increased drug load can be observed during the
direct disposal of a large quantity of illicit drug during a police
raid of an illegal production factory. To demonstrate, Emke
et al. (2014) observed a load of MDMA 20 times higher than
normal during a weekly sampling campaign at a WwTW in
Utrecht. Direct disposal was considered to be the source of
this spike based on findings of enantiomeric profiling (i.e., no
metabolism) (Fig. 4). This irregularly high load coincided with
a police raid within the catchment two days earlier. However,Fig. 4 e Load of MDMA in wastewater collected during
week long sampling campaigns conducted in 2010 and
2011 (a) and their corresponding enantiomeric fraction (b)
e adapted from Emke et al. (2014). Note: Enantiomeric
fraction ¼ (þ)/[(þ)þ(¡)] e 0.5 denotes a racemic
distribution.such events are difficult to monitor due to their unpredictable
occurrence. A further scenario which could result in a sharp
increased load of a drug within the environment is in the
event of a pandemic. A UK outbreak of influenza in 2009
resulted in a high number of people treated with antivirals
and antibiotics (Singer et al., 2011; Slater et al., 2011; Singer
et al., 2013). There is limited knowledge of the resilience of
WwTWs to maintain normal performance and achieve anti-
biotic removal in such events. Nevertheless, laboratory scale
investigation showed that typically reported concentrations
of oseltamivir carboxylate (the active metabolite of Tamiflu®,
the medicine used in response to the influenza outbreak)
reduced activated sludge performance with respect to
nutrient removal (Slater et al., 2011).
3.2. Partitioning of ECs to solid matter during
wastewater treatment
3.2.1. Influent wastewater and final effluent
Emerging contaminant analysis in wastewaters tends to be
undertaken on the aqueous phase only (i.e., a pre-filtered
sample) (Table 1). Particulate phase analysis is not routinely
undertaken because up to one gram of dry solids is often
required for each analysis and additional sample extraction is
needed (Radjenovic et al., 2009a; Baker and Kasprzyk-Hordern,
2011b). However, analysis here is essential as some chemicals
have a high affinity to particulate matter. Numerous chem-
icals including amitriptyline, EMDP, dosulepin, fluoxetine,
norfluoxetine, triclosan, ofloxacin and ciprofloxacin have
been found to be within the particulate phase of influent
wastewater at significant concentrations (>20% of the total
concentration) (Baker and Kasprzyk-Hordern, 2011a,b; Petrie
et al., 2014c). Consequently, particulate phase determination
is necessary to correctly report influent concentration for
some chemicals. This is also essential for back calculations of
population usage by wastewater-based epidemiology (Baker
et al., 2012). Partitioning of ECs to suspended matter in final
effluents is even less studied due to the very low solids con-
centrations encountered (typically 10e30mg l1 for secondary
processes). Nevertheless, Petrie et al. (2014c) found that final
effluent of secondary processes had >20% of the total triclo-
san, ofloxacin and ciprofloxacin concentration to be within
the particulate phase, despite very low suspended solids
concentrations. Particulate phase concentrations were
equivalent to, and in the range 26e296 ng l1, respectively.
This provides a route for their release into the environment
which goes unmonitored and the environmental fate of these
particulate bound chemicals is unknown.
3.2.2. Diagnosis of EC removal during wastewater treatment
Common sampling approaches to measure wastewater
treatment performance with respect to EC removal monitor
aqueous phase of influent and effluent samples only (Table 1).
To better understand their pathways of removal during
wastewater treatment, particulate phase analysis is needed as
well as analysis of the biomass (either suspended or attached)
of the process (Petrie et al., 2014a,c). Ideally, corresponding
aqueous and particulate determinations should be under-
taken for each sampling point such that a complete process
mass balance is attained. This can give valuable information
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et al., 2014a,c). Removal can vary greatly between ECs from a
physically driven process (adsorption) to biologically medi-
ated enzymatic reactions (biodegradation) (Helbling et al.,
2010; Petrie et al., 2014a). Their identification also needs to
be supported with information of process conditions and
operation, nutrient removal and complimentary analysis of
the physical/biological characterisation of biomass (Petrie
et al., 2014a). With this knowledge, the operation of the pro-
cess could be adjusted to favour their removal (Petrie et al.,
2014b). Such information can also be used to identify where
further research efforts may be needed. For example, those
chemicals removed by biodegradation suggest further inves-
tigation of possible biotransformation products in final efflu-
ents is needed, and those removed by adsorption require
further understanding of their fate during and following
sludge treatment.
3.2.3. Biosolids and amended soils
During anaerobic digestion, biosolids (or treated sludge) are
generated. These are often applied to agricultural land as a
fertiliser in some countries. Despite lengthy digestion (20e30
days) and outdoor storage for up to six months following
treatment, some ECs have shown to persist (Cortes et al.,
2013). No legislation currently controls the use of biosolids
on agricultural land with respect to concentration of ECs.
Consequently, a lack of analysis has been observed here
(Table 2). Themajority of chemicals previously investigated in
biosolids were found at <1 mg kg1. On the other hand
bisphenol A, triclosan, triclocarban and the antibiotics cipro-
floxacin, ofloxacin and norfloxacin have all been reported at
>1 mg kg1 (Table 2) (Golet et al., 2002; McAvoy et al., 2002;
Lindberg et al., 2005; Morales et al., 2005; Heidler et al., 2006;
Chu and Metcalfe, 2007; Ying and Kookana, 2007; Stasinakis
et al., 2008; Cha and Cupples, 2009; Langdon et al., 2011;
Gottschall et al., 2012; Sabourin et al., 2012; Guerra et al.,
2014). These chemicals have very different physicochemical
properties (hydrophobicity, water solubility etc) (Table 2),
suggesting their fate and transport in amended soils will vary
(Morais et al., 2013). Triclosan and triclocarban exhibit greater
hydrophobicity (log Kow 4.2e4.8) indicative of retention within
the soil matrix. In contrast, those which are relatively water
soluble (3.0  104 mg l1 e ciprofloxacin, norfloxacin and
ofloxacin) suggest hydrophilic mobility which may result in
their transport to surrounding surface waters. However, Tolls
(2001) demonstrated that antibiotics show a wide range of
mobility in soil. This implies othermechanisms are likely to be
important, particularly for charged ECs. Partitioning behav-
iour of charged ECs is likely to be governed by other mecha-
nisms such as electrostatic attractions (Hyland et al., 2012). If
charge interactions play a role in sorption, then the Kow
concept is not meaningful here and cannot be applied.
Therefore the acid-dissociation constant (pKa) of the EC in
question and pH of the matrix are critical for better under-
standing partitioning behaviour. For those ECs which are
ionisable, the pH dependant octanolewater coefficient (log
Dow) should be applied to account for different behaviour.
To better appreciate the fate of ECs in soils, long term field
studies at real environmental conditions are needed. These
require sampling of biosolids, soil (pre- and post-application,and at various depths), surrounding surface waters and up-
take by plants over an extended time period. Supporting in-
formation of pH, rainfall, temperature, sunlight and soil type/
characteristics would help understand their fate. An excellent
study by Butler et al. (2012) found that following biosolids
application, triclosan (~0.8e1.0 mg kg1) showed little change
in concentration over the initial eight months for three
different soil types. However, after 12months less than 20% of
the initial concentrationwas recovered. A large fraction of this
was attributed to the biological transformation of triclosan to
methyl triclosan. Methyl triclosan was observed up to
0.4 mg kg1, demonstrating that transformation products
need to be investigated here.
3.3. Fate of ECs in environmental waters
3.3.1. Human metabolites
Parent chemicals are often excreted from the human body
with a number of associated metabolites. As an example,
ibuprofen is excreted as the unchanged drug (1%) and several
metabolites: (þ)-2-40-(2-Hydroxy-2-methylpropyl)-phenyl-
propionic acid (25%), (þ)-2-40-(2-carboxypropyl)-phenyl-
propionic acid (37%) and conjugated ibuprofen (14%)
(Kasprzyk-Hordern et al., 2008b). However, only ~20% of ECs
previously reported in UK waters were metabolites (Table 1),
and this is mirrored in international studies (Gros et al., 2012;
Hughes et al., 2013; Lopez-Serna et al., 2013). Admittedly their
determination has been restricted by a lack of available
analytical reference standards. Despite this, their determina-
tion is essential as free parent ECs are often cleaved from
human metabolites and in particular, glucuronide conjugates
when exposed to environmental conditions (Ternes et al.,
1999). This has been observed in crude sewage and activated
sludge batch studies for steroid estrogens (17a-EE2 3-
glucuronide, estriol 16a-glucuronide, and estrone 3-
glucuronide) (Gomes et al., 2009) and suggested to occur spe-
cifically for carbamazepine during full-scale activated sludge
treatment (Vieno et al., 2007). Furthermore, analysis of me-
tabolites is necessary as they can be found at concentrations
much greater than the corresponding parent chemical and
can themselves be pharmacologically active (Kasprzyk-
Hordern et al., 2008b). To demonstrate, a major metabolite of
carbamazepine (carbamazepine epoxide) has been found in
influent wastewater at concentrations ranging from 880 to
4026 ng l1 whereas the parent compound was found at
<1.5e113 ng l1 (Huerta-Fontela et al., 2010). Metabolites can
also be persistent during secondary wastewater treatment
(Lajeunesse et al., 2012; Petrie et al., 2013b). Their release into
the environment and the possibility of subsequent biotrans-
formation/deconjugation in environmental compartments to
the parent EC makes their determination essential to better
assess ecological risk.
3.3.2. Microbial transformation
Many ECs undergo microbially mediated reactions during
secondary wastewater treatment (Helbling et al., 2010), and in
the environment. Biodegradation is often referred to as the
dominant fate pathway for the removal of some ECs from the
aqueous phase of wastewaters and surface waters (Andersen
et al., 2005; Bagnall et al., 2012a,b). However, this can result in
Table 2 e Concentration and physicochemical properties (ChemicalBook, 2014; ChemSpider, 2014; DrugBank, 2014) of ECs
found in biosolids (n ≥ 3).
Emerging
contaminant
Log Kow pKa Water
solubility (mg l1)
Country Mean biosolid conc.
(mg kg1 dry weight)
Reference
Estrone 3.13 10.3 30.0 Germany <MQL-0.02 Ternes et al., 2002
Canada 0.06 Sabourin et al., 2012
Australia <MQL-0.28 Langdon et al., 2011
Ibuprofen 3.97 4.91 21.0 Spain 0.30 Radjenovic et al., 2009a
Canada 0.15a Guerra et al., 2014
Spain 0.02e0.44 Albero et al., 2014
Canada 0.17 Sabourin et al., 2012
Canada 0.06 Gottschall et al., 2012
Spain 0.09 Morais et al., 2013
Naproxen 3.18 4.15 15.9 Canada 0.02a Guerra et al., 2014
Spain <MQL-0.02 Albero et al., 2014
Canada 0.01 Sabourin et al., 2012
Diclofenac 4.51 4.15 2.37 Spain 0.19 Radjenovic et al., 2009a
Spain <MQL-0.63 Albero et al., 2014
Spain 0.06 Morais et al., 2013
Canada <MQL-0.02 Spongberg and Witter, 2008
Acetaminophen 0.460 9.38 1.40  104 Spain 0.03 Radjenovic et al., 2009a
USA <MQL-0.37 Ding et al., 2011
Canada 0.02a Guerra et al., 2014
Spain 0.02e0.29 Albero et al., 2014
Gemfibrozil 3.40 4.75 e Spain 0.12 Radjenovic et al., 2009a
Spain <MQL-0.07 Albero et al., 2014
Canada 0.008 Sabourin et al., 2012
Canada <MQL-0.003 Spongberg and Witter, 2008
Carbamazepine 2.45 13.9 17.7 Spain 0.08 Radjenovic et al., 2009a
USA <MQL-0.02 Ding et al., 2011
Canada 0.26 Miao et al., 2005
Canada 0.18 Gottschall et al., 2012
Canada 0.09 Sabourin et al., 2012
Spain 0.03 Morais et al., 2013
Canada 0.01 Spongberg and Witter, 2008
Fluoxetine 4.05 3.95 5.00  104 Spain 0.12 Radjenovic et al., 2009a,b
Canada 0.09 Sabourin et al., 2012
Canada 0.11 Gottschall et al., 2012
Propranolol 3.48 9.42 61.7 Spain 0.03 Radjenovic et al., 2009a
Canada 0.04 Sabourin et al., 2012
Canada 0.12 Gottschall et al., 2012
Canada 0.36a Guerra et al., 2014
Canada 0.23 Gottschall et al., 2012
Ciprofloxacin 0.280 6.09 3.00  104 Switzerland 2.27e2.42 Golet et al., 2002
Sweden 0.50e4.80 Lindberg et al., 2005
Canada 6.50a Guerra et al., 2014
Canada 5.87 Sabourin et al., 2012
Canada 3.26 Gottschall et al., 2012
Canada <MQL-0.05 Spongberg and Witter, 2008
Norfloxacin 1.03 2.75 1.78  105 Switzerland 2.13e2.37 Golet et al., 2002
Sweden 0.10e4.20 Lindberg et al., 2005
Canada 1.75 Sabourin et al., 2012
Canada 1.01 Gottschall et al., 2012
Ofloxacin 0.390 5.23 2.83  104 Sweden <MQL-2.00 Lindberg et al., 2005
Spain 0.07 Radjenovic et al., 2009a,b
Canada 0.69a Guerra et al., 2014
Canada 1.07 Sabourin et al., 2012
Canada 1.40 Gottschall et al., 2012
Tetracycline 1.30 3.30 5.00  104 USA <MQL-0.56 Ding et al., 2011
Canada 0.24a Guerra et al., 2014
Canada 0.34 Sabourin et al., 2012
Canada 0.51 Gottschall et al., 2012
Canada <MQL-0.01 Spongberg and Witter, 2008
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Table 2 e (continued )
Emerging
contaminant
Log Kow pKa Water
solubility (mg l1)
Country Mean biosolid conc.
(mg kg1 dry weight)
Reference
Triclosan 4.80 7.90 10.0 Greece 3.21 Stasinakis et al., 2008
USA 0.53e15.6 McAvoy et al., 2002
Spain 1.51 Morales et al., 2005
Canada 0.68e11.55 Chu and Metcalfe, 2007
Australia 5.58 Ying and Kookana, 2007
USA 4.89e9.28 Cha and Cupples, 2009
Canada 6.80a Guerra et al., 2014
Canada 4.68 Sabourin et al., 2012
Canada 10.9 Gottschall et al., 2012
Australia 0.22e9.89 Langdon et al., 2011
Triclocarban 4.20 12.7 0.110 Canada 3.05e5.97 Chu and Metcalfe, 2007
USA 0.09e7.06 Cha and Cupples, 2009
USA 51.0 Heidler et al., 2006
Canada 2.90a Guerra et al., 2014
Canada 6.03 Sabourin et al., 2012
Canada 4.94 Gottschall et al., 2012
Bisphenol A 3.43 10.3 120 Greece 0.53 Stasinakis et al., 2008
China 0.01 Song et al., 2014
Australia 0.06e1.37 Langdon et al., 2011
Key: Log Kow, octanolewater coefficient; pKa, acid dissociation co-efficient; MQL, method quantitation limit.
a Reported as median.
wa t e r r e s e a r c h 7 2 ( 2 0 1 5 ) 3e2 7 15the formation of numerous degradation or transformation
products. These are not well studied as typical targeted
screening approaches for known compounds (low resolution
mass spectrometry utilising triple quadrupoles technology)
are not capable of their identification. Also, as biotransfor-
mation pathways are not often known, there are very few
standards available for these transformation products.
Helbling et al. (2010) successfully identified previously unre-
ported biological transformation products for the pharma-
ceuticals bezafibrate, diazepam (Fig. 5a), levetiracetam,
oseltamivir and valsartan using high resolution mass spec-
trometry (linear ion trap-orbitrap technology) during(a)
Fig. 5 e Transformation pathways of diazepam during activated
and when exposed to simulated sunlight (b) e adapted from Wlaboratory scale investigation of activated sludge. Trans-
formation products have also been reported at indigenous
concentrations in final effluents of activated sludge WwTWs
(Gomez et al., 2010). Gomez et al. (2010) identified trans-
formation products of acetaminophen (P-aminophenol) and
azithromycin (unnamed compound) by non-targeted
screening using quadrupole time of flight (QTOF) mass spec-
trometry. Their identification is essential as these can bemore
toxic than the parent compound as is the case with P-ami-
nophenol (Bloomfield, 2002; Gomez et al., 2010). Therefore
removal of the parent EC does not necessarily translate into
removal of toxicity. Considering the high number of parent(b)
sludge treatment (a) e adapted from Helbling et al. (2010)
est and Rowland (2012).
wat e r r e s e a r c h 7 2 ( 2 0 1 5 ) 3e2 716ECs in wastewater (Table 1) (Hughes et al., 2013), it is expected
that a great number of transformation products (of unknown
toxicity and persistence) exist in final effluent and receiving
surface waters.
3.3.3. Physicochemical processes
Physicochemical mechanisms can also contribute to EC
removal from wastewaters and surface waters. Sorption onto
biomass during wastewater treatment, or into sediments
when present in the riverine environment will result in
removal from the aqueous phase. However, this is only likely
to hold true for some ECs. For example, if equilibrium is
established between the biomass or sediment and the
aqueous medium for a specific EC, the net exchange between
the two phases (and removal from the aqueous phase) will be
zero (Schwarzenbach et al., 2003). Therefore sorption will not
contribute to their removal. This has been observed across
activated sludge WwTWs for some ECs such as steroid estro-
gens (Andersen et al., 2005; Petrie et al., 2014a). On the other
hand, the antibiotics ofloxacin and ciprofloxacin were shown
to be removed by sorption during wastewater treatment due
to their high affinity to solid organic matter (Petrie et al.,
2014c). Therefore understanding the role of physicochemical
properties to the sorption of these ECs is essential. Consider-
ation must also be given to the impact of dissolved organic
matter to the fate of ECs in the environment. Binding of ECs to
dissolved organic matter could help retain ECs in the aqueous
phase of environmental matrices. Furthermore, formation of
EC-dissolved organic matter complexes may lead to the EC
going undetected during analysis.
When present in the aqueous environment, ECs are sus-
ceptible to breakdown by photolysis. Photolysis has been
shown to successfully degrade several ECs such as ketoprofen,
propranolol, naproxen, E2, EE2, gemfibrozil and ibuprofen in
river water (Lin and Reinhard, 2005). Half-lives ranged broadly
from four minutes for ketoprofen to 15 h for gemfibrozil and
ibuprofen. This range of susceptibility to breakdown by
photolysis observed is attributed to differences in their
chemical structure. For example, the carbonyl moiety of
ketoprofen is in conjugation with two aromatic rings which
results in a very reactive triple state and a high susceptibility
to breakdown by photolysis (Lin and Reinhard, 2005). There-
fore photolysis can contribute notably to the removal of a
number of ECs from surface waters. As with biological
degradation, removal of the parent compound by photolysis is
not indicative of complete mineralisation and several trans-
formation products can be observed (Fig. 5b). Therefore a
reduction in toxicity may not be observed with removal of the
parent compound. It can be postulated that the presence of
dissolved organic matter of comparatively high concentra-
tion, as well as particulates in environmental waters will
reduce EC degradation kinetics by clouding sunlight intensity.
However, West and Rowland (2012) found that humic acid (a
small molecular weight charged species) slowed or increased
degradation rate, dependant on the specific EC investigated.
Increased degradation in the presence of humic acid or ni-
trates can be attributed to indirect photolysis (Andreozzi et al.,
2003). Wastewater effluents contain hydroxyl radicals and
triplet excited state organic matter which facilitates indirect
photolysis of some ECs (Ryan et al., 2011). Otherenvironmental factors such as depth of river, shading from
bankside vegetation, presence of particulate matter and sea-
son also require further investigation to assess their impact to
EC photolysis in environmental conditions.
3.4. Toxicological impact of ECs within the environment
3.4.1. Collated acute toxicity information
Testing aquatic ecotoxicity of ECs is usually undertaken at
controlled laboratory conditions. This often involves deter-
mining acute toxicity of a single compound to a specific in-
dicator species. The most common taxon is the crustacean
Daphnia magna, with standard methods available to measure
EC50 based on their mobility (OECD, 2004). These methods are
conducted in an exposure medium consisting of clean labo-
ratory water. Such tests are an excellent indicator of the po-
tential risks posed by individual chemicals. The general
approach is to classify those with an EC50 between 10 and
100 mg l1 as harmful, from 1 to 10 mg l1 as toxic, and those
<1 mg l1 as very toxic to aquatic organisms (Commission of
the European Communities, 1996; Cleuvers, 2003). Collation of
EC50data from different literature sources has limitations due
to the range of test species used, as well as the variety of
toxicological endpoints studied. Effect concentrations will be
dependent on the test species studied as ECs can cause
different toxicological responses between different species.
Despite this, collated data can give an indication of toxicity for
the most well studied ECs (Fig. 6). Non-steroidal anti-inflam-
matory drugs (acetaminophen, ibuprofen, diclofenac and
naproxen), lipid regulators (bezafibrate, clofibric acid e
metabolite), carbamazepine and trimethoprim are generally
classified as harmful to aquatic organisms. Other antibiotics
(ofloxacin, sulfamethoxazole, oxytetracycline, erythromycin)
mostly fall within the toxic range. However, there is also a lack
of information on the synergistic impact of these chemicals,
particularly at low concentration over longer exposure times.
3.4.2. Impact of mixtures and chronic impact
Aquatic biota within the receiving environment is continually
exposed to a complexmixture of ECs. Studies have shown that
mixtures of pharmaceuticals exhibit greater effect than the
compounds individually. To demonstrate, the antiepileptic
carbamazepine and the lipid lowering agent clofibric acid
(which belong to very different therapeutic classes and
expectant modes of action), exhibited stronger effects to D.
magna during immobilization tests than the single com-
pounds at the same concentration (Cleuvers, 2003). Further-
more, Cleuvers (2004) reported considerable acute toxicity for
a mixture of NSAIDs (diclofenac, ibuprofen, naproxen and
aspirin) at the same concentration where little or no effect
was observed for the chemicals individually. This underpins
the need to assess chronic impact of EC mixtures at environ-
mentally relevant concentrations, as well as undertaking
whole life cycle determinations. However, this is very difficult
to ascertain over long time periods where relatively subtle
toxicological responses are observed in comparison to acute
effects such as death ormobility which are easily measurable.
Nevertheless, increasing numbers of studies assessing the
chronic impact of EC mixtures have found significant effects.
For example, female Danio rerio exposed to a pharmaceutical
Fig. 6 e Ecotoxicity EC50 information (n ≥ 5) available in the literature for ECs reported for a minimum of three different
species types with boxes showing interquartile range and median, and whiskers showing range, outliers also shown. It
should be noted that collated toxicological response information only gives a subjective insight into toxicity as this is highly
dependent on the test species studied as ECs can cause varying toxicological responses between species type. Data obtained
from: (Henschel et al., 1997; Holten Lu¨tzhøft et al., 1999; Wollenberger et al., 2000; Cleuvers, 2003; Ferrari et al., 2003; Pro
et al., 2003; Cleuvers, 2004; Eguchi et al., 2004; Pomati et al., 2004; Cleuvers, 2005; Isidori et al., 2005a,b; Heckmann et al.,
2007; Isidori et al., 2007; Kim et al., 2007; DeLorenzo and Fleming, 2008; Park and Choi, 2008; Quinn et al., 2008b; De Liguoro
et al., 2009; Rosal et al., 2010; Han et al., 2010; Van den Brandhof and Montforts, 2010; Dave and Herger, 2012). EC50's
classified as <1 mg l¡1 ¼ very toxic to aquatic organisms, 1e10 mg l¡1 ¼ toxic to aquatic organisms,
10e100 mg l¡1 ¼ harmful to aquatic organisms and >100 mg l¡1 ¼ not classified (Commission of the European
Communities, 1996; Cleuvers, 2003).
wa t e r r e s e a r c h 7 2 ( 2 0 1 5 ) 3e2 7 17mixture (acetaminophen, carbamazepine, gemfibrozil and
venlafaxine) as well as WwTW effluent showed significant
reductions in embryo production over a sixweek period (Galus
et al., 2013). Also, Dietrich et al. (2010) investigated single
compound andmixture toxicity of carbamazepine (500 ng l1),
diclofenac (360 ng l1), EE2 (0.1 ng l1) and metoprolol
(1200 ng l1) to D. magna over six generations. These concen-
trations were selected to represent environmentally relevant
concentrations for river waters in Germany (Dietrich et al.,
2010). However, the influence of the pharmaceutical mixture
was inconsistent and unpredictable. This is in disagreement
to acute toxicity testing of pharmaceutical mixtures con-
ducted at greater concentrations (Cleuvers, 2003, 2004). Also,
no relationship in toxicological effect was observed for suc-
cessive generations of D. magna. It was postulated that this
may be due to the development of resistance towards the
pharmaceuticals (Dietrich et al., 2010). It is clear that further
studies are needed to confirm the chronic impact of multipleECs synergistically, whilst at low concentration. Furthermore,
these studies need to assess ecological impact to organisms of
different trophic levels. Consideration must also be given to
the exposure medium used. Surface waters contain dissolved
organic matter which could potentially reduce compound
bioavailability. This is not currently considered in existing
laboratory toxicity testing protocols.
3.4.3. Illicit drugs
Despite numerous illicit drugs being reported in surface wa-
ters (Table 1) and the possibility of shock loads which can be
encountered (Emke et al., 2014), there are only a few experi-
mental studies which have investigated toxicity to aquatic
organisms. Illicit drugs are potent in nature therefore a high
toxicity to exposed aquatic organisms is inferred. Parolini and
Binelli (2014) investigated oxidative and genetic responses
induced by D-9-tetrahydrocannabinol (main psychoactive
compound of cannabis) to the mollusc Dreissena polymorpha
Table 3 e Toxicological response of chiral enantiomers and their enantiomeric distribution in the environment.
Emerging
contaminant
Enantiomer Toxicological response of chiral enantiomers Distribution of chiral enantiomers within the environment
Potency within the
human body
Toxicity to aquatic
organisms
Country Surface water Enantiomeric
fraction
Reference
Ibuprofen S(); R(þ) S > 100 times more potenta e Switzerland Lakes and rivers 0.41e0.47 Buser et al., 1999
Spain Rivers 0.30e0.50 Lopez-Serna et al., 2013
Australia River 0.60e0.80 Khan et al., 2013
China Canal and river 0.13e0.33 Wang et al., 2013
Naproxen S(); R() S more potentk e Australia River 1.00 Khan et al., 2013
Propranolol S(); R(þ) S 100 times more activea Similar acute response to
P. promelas and D. magnac
USA Rivers 0.21e0.53 Fono and Sedlak, 2005
S higher chronic toxicity
to P. promelasc
UK River 0.45 Bagnall et al., 2012a,b
S and R chronic toxicity
similar to D. magnac
Spain Rivers 0.38e0.60 Lopez-Serna et al., 2013
Atenolol S(); R(þ) S more potentf S ~4 times more toxic to
T. thermophilad
UK River 0.38e0.56 Kasprzyk-Hordern
and Baker, 2012b
R ~2 times more toxic to
D. magnad
UK River 0.47 Bagnall et al., 2012a,b
S and R toxic effects similar
to P. subcapitad
Spain Rivers 0.38e0.50 Lopez-Serna et al., 2013
Sotalol R/S(±) R possesses majority of
b-blocking activityh
e Spain Rivers 0.41e0.65 Lopez-Serna et al., 2013
Metoprolol R/S(±) S 35 times more potentg e Spain Rivers 0.42e0.51 Lopez-Serna et al., 2013
Germany River 0.43e0.46 Kunkel and Radke et al., 2012
Fluoxetine S(þ); R() S and R have different
pharmacological activitye,i
S ~10 times more toxic to
P. promelasb
Spain Rivers 0.64e0.68 Lopez-Serna et al., 2013
S and R toxic effects similar
to D. magnab,d
S ~10 times more toxic to
T. thermophilad
Norfluoxetine R/S(±) Enantiomers have
different potencyi
e Spain Rivers 0.76 Lopez-Serna et al., 2013
Venlafaxine R/S(±) R more potentj e UK River 0.40e0.65 Kasprzyk-Hordern and
Baker, 2012b
UK River 0.58 Bagnall et al., 2012a,b
France River 0.46e0.74 Li et al., 2013
Ephedrine 1R,2S(); 1S,2R(þ) e e UK River 0.79e1.00 Kasprzyk-Hordern and
Baker, 2012b
MDMA S(þ); R() S more potentl e UK River 0.56e0.81 Kasprzyk-Hordern and
Baker, 2012b
MDA R/S(±) S more potentl e UK River 0.56e0.58 Kasprzyk-Hordern and
Baker, 2012b
Amphetamine S(þ); R() Dextro enantiomer
more potento
e UK River 0.81e0.86 Kasprzyk-Hordern and
Baker, 2012b
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wa t e r r e s e a r c h 7 2 ( 2 0 1 5 ) 3e2 7 19(zebra mussel). Concentrations of 500 ng l1 over a 14 day
exposure period led to notable changes in oxidative status.
This could lead to increased lipid peroxidation, protein
carbonylation and DNA damage (Parolini and Binelli, 2014).
The possible effects of cocaine and its metabolites to aquatic
organisms have been given more attention (Binelli et al., 2012;
Parolini et al., 2013; Parolini and Binelli, 2013). An initial study
investigated cyto-genetoxic effects of cocaine to D. polymorpha
at concentrations of 40, 220 and 10,000 ng l1 (Binelli et al.,
2012). Primary DNA damage, increased micro-nucleated cells
and apoptosis were all observed after an exposure time of
96 h, even at the lowest exposure concentration (40 ng l1). An
investigation of sub-lethal effects of benzoylecgonine showed
enzyme defence chain imbalances of D. polymorpha at
500 ng l1 for a 14 day time period (Parolini et al., 2013). Finally,
a study of ecognine methyl ester (another cocaine metabolite)
found 14 days exposure to 500 ng l1 induced destabilization
of lysosome membranes, inactivation of defence enzymes,
increased lipid peroxidation, protein carbonylation and DNA
fragmentation of D. polymorpha (Parolini and Binelli, 2013).
These studies have given an excellent insight into the toxicity
of illicit drugs to aquatic organisms. Toxicity testing of illicit
drugs should be expanded to include compounds such as
MDMA, which have not been investigated previously. Addi-
tionally, these findings need to be supported with standard
toxicity testing protocols for a variety of accepted indicator
species types. Coupled with environmental occurrence infor-
mation, this would help prioritise those chemicals which
require immediate in-depth investigation of their fate and
ecological impact.
3.4.4. River sediments and amended soils
Emerging contaminants have also been reported in riverine
sediments (Da Silva et al., 2011; Azzouz and Ballesteros, 2012;
Chen and Zhou, 2014). Determining toxicological impact here
is essential as sediments can act as a sink for their accumu-
lation. However, this is notoriously difficult to ascertain due to
the complexity of the system. Benthic organisms can be
exposed to ECs within the sediment itself, in interstitial water
and in overlying water (Gilroy et al., 2012). This makes
experimental design and set-up critical for reproducing
representative conditions. A study investigating toxicity of
diclofenac to the crustacean Hyalella azteca, prepared syn-
thetic sediment at a 1:3 ratio with water (Oviedo-Gomez et al.,
2010). The authors failed to report or investigate aqueous/
liquid partitioning of diclofenac, whether equilibrium condi-
tions were present or if desorption occurred throughout the
test. Consequently, reporting toxicological effect concentra-
tions for sediments can have considerable uncertainties. An
improved study by Gilroy et al. (2012) supported biological
response information with chemical analysis for both
aqueous and particulate phases. Findings suggested that
sorption to sediments resulted in a reduction of bioavailability
and toxicity. On the other hand, the accumulation (and
increased concentration) of readily sorbed compounds in
sediments within the environment could compensate for this
reduction in toxicity. Interestingly, the activity of benthic
invertebrate also resulted in increased desorption, leading to
improved bioavailability (Gilroy et al., 2012). Numerous
mechanisms take place, illustrating the complexity of
wat e r r e s e a r c h 7 2 ( 2 0 1 5 ) 3e2 720ascertaining sediment toxicity. Studies over long time periods
which simulate representative steady-state riverine sediment
conditions are required for a range of indicator species. These
firstly need to be supported with chemical analysis to assess
the behaviour of the EC(s) in question. Such studies would
help assess chronic and multi-generation impact of sediment
contamination to benthic organisms. Similarly (and as dis-
cussed previously e Section 3.2.3), amended soils can also
contain significant concentrations of some municipal derived
ECs. The resulting toxicity to terrestrial organisms is poorly
understood due to the lack of knowledge on their occurrence
to drive investigation of their toxicological impact. Also, no
standard methods are available which can easily measure
toxicity to exposed terrestrial organisms. Nevertheless, indi-
rect methods such as soil respiration rate can be used to
measure possible impact to the soil community (Butler et al.,
2011). These need to be supported with controlled single
(and multi) compound toxicity testing with predetermined
indicator species to help understand the ecological impact of
applying biosolids to agricultural soils.
3.4.5. Chirality
Pharmaceuticals are often prepared and dispensed as racemic
mixtures (i.e., a 50:50 mixture of two enantiomers). Meta-
bolism within the human body and exposure to biological
mediated reactions duringwastewater treatment can result in
the enrichment of one specific enantiomer. On the other hand,
some pharmaceuticals such as NSAIDs are marketed as a
single enantiomer. Chiral inversion can lead to the distribu-
tion of two enantiomers. This has been observed for naproxen
during biological wastewater treatment (Hashim et al., 2011).
However, conventional analytical approaches are not able to
distinguish between enantiomers of the same compound
(Evans and Kasprzyk-Hordern, 2014). As a result there is a
paucity of information on the enantiomeric distribution of
chiral compounds within the environment. Nevertheless,
available information in the literature show chiral ECs to be
mostly non-racemic when present in surface waters (Table 3).
Enantiomeric fractions range broadly from 0.1 for ibuprofen
(Wang et al., 2013) to 1.0 for naproxen and ephedrine
(Kasprzyk-Hordern and Baker, 2012b; Khan et al., 2013) (an
enantiomeric fraction of 0.5 denotes a racemic mixture).
Concern arises from the large amount of toxicity testing being
undertaken with racemic mixtures (or unknown/not reported
enantiomeric composition) of the chemical under investiga-
tion (Fig. 6) (Henschel et al., 1997; Holten Lu¨tzhøft et al., 1999;
Wollenberger et al., 2000; Cleuvers, 2003; Ferrari et al., 2003;
Pro et al., 2003; Cleuvers, 2004; Eguchi et al., 2004; Pomati
et al., 2004; Cleuvers, 2005; Isidori et al., 2005a,b; Heckmann
et al., 2007; Isidori et al., 2007; Kim et al., 2007; DeLorenzo
and Fleming, 2008; Park and Choi, 2008; Quinn et al., 2008b;
De Liguoro et al., 2009; Rosal et al., 2010; Han et al., 2010;
Van den Brandhof and Montforts, 2010; Dave and Herger,
2012). However, the toxicological response and potency of
pharmaceuticals in the human body is known to differ be-
tween enantiomers of the same chemical (Table 3). For
example, the S-enantiomer of ibuprofen is 100 times more
active than R-enantiomer (Kasprzyk-Hordern, 2010). This
suggests that their toxicity to organisms within the environ-
ment will also differ. The few studies which have beenundertaken at the enantiomeric level showed significantly
different toxic responses for some aquatic taxa (Table 3)
(Stanley et al., 2006, 2007; De Andres et al., 2009). To demon-
strate, S-fluoxetine was found to be ~10 times more toxic to P.
promelas and T. thermophila than R-fluoxetine (Stanley et al.,
2007; De Andres et al., 2009). Toxiclogical effect information
gained from current ecotoxicity testing which use racemic
mixturesmay therefore underestimate the risk actually posed
in the environment. Findings from racemic toxicity testing
have been used to recommend predicted effect/no effect
concentrations (Ferrari et al., 2004; Quinn et al., 2008a; Martins
et al., 2012) and can be seen as a precursor for environmental
legislation and the proposal of quality standards. Although
environmental legislation has safety buffers incorporated into
their derivation, failure to recognise the enantiomeric distri-
bution of chiral compounds in the environment and a lack of
information on the toxicological differences between enan-
tiomers is concerning.4. Future recommendations for
environmental monitoring of ECs
4.1. Sampling mode and strategy
Arguably, the most important step in monitoring for ECs in
wastewaters and in the environment is sampling. This is
fundamental to obtaining representative data. To monitor
treatment process performance for the removal of ECs, cor-
responding grab samples can be used to compensate for hy-
draulic retention time (HRT) (Petrie et al., 2013b,c; 2014c). This
approach can monitor performance of processes such as
trickling filters which operate at comparatively short HRTs
(<2 h). However, this is not practical for systems such as
activated sludge which often operate at HRTs 6 h. Corre-
sponding grab samples are also typically taken once daily and
do not enable the performance of the process to be fully un-
derstood. For example, pollutant removal at daily peak flows
(between 7:00 and 9:00 h) and during low flow spells (3:00 to
5:00 h) are not appreciated. Therefore a sampling approach is
needed which can: (i) obtain a composite sample representa-
tive of a system over a longer period of time (e.g., a 24 h time
period and flow or volume proportional) and, (ii) can ensure
the stability of analytes by using a suitable preservation
technique (i.e., acidification or addition of sodium azide
(Hillebrand et al., 2013)). Although collecting flow proportional
samples has logistical issues for the deployment of sampling
equipment (samplers and flow measurement devices) at
suitable locations across WwTWs or on rivers, their use is
paramount to attaining representative measurements during
environmental monitoring. Alternatively, passive samplers
could be considered but these require further investigation to
establish their suitability for the uptake of more polar chem-
icals such as ECs (Mills et al., 2014). Ideally, in situ real-time
sensors would be used. In any case sampling campaigns
should be at least oneweek in length to incorporate weekends
where substantial variations in flow and EC load are likely.
Furthermore, the frequency of repeat sampling campaigns
throughout the year needs consideration. A minimum of two
sampling events per year (summer/winter) to reflect the
wa t e r r e s e a r c h 7 2 ( 2 0 1 5 ) 3e2 7 21dynamics of seasonal change is recommended. This will
enable seasonal usage patterns of EC to be established, as well
as the impact of temperature on WwTW performance. The
sampling strategy itself must consider attaining complete
mass balances for the WwTW or stretch of river system in
question. Analysis of waste/recycled sludge and river sedi-
ment are essential to determine fate of ECs across such sys-
tems. This includes particulate phase analysis of all sampling
positions (Petrie et al., 2014c). Admittedly this will be prob-
lematic to obtain for final effluents over a complete sampling
campaign. However, determination of final effluent particu-
late phase concentrations at least once during the sampling
campaign is valuable, considering the lack of analysis previ-
ously undertaken here.
4.2. Analysis methods
Analytical methods which can determine ECs at the enantio-
meric level are recommended. However, achieving multi-
residue separations with chiral stationary phases is difficult
due to their highly specific nature and a poor understanding of
the separationmechanism. Also, themaximumback pressure
of chiral columns is generally ~2000 psi which limits their
operation to high-performance liquid chromatography mode.
Consequently, run times are often 60 min (Kasprzyk-
Hordern et al., 2010; Bagnall et al., 2012a,b; Lopez-Serna
et al., 2013), restricting sample throughput and turnover.
Stationary phases comprised of smaller particle sizes (i.e.,
<2 mm) which can achieve the performance of ultra-
performance liquid chromatography (UPLC) in terms of run
time and column efficiency (Evans and Kasprzyk-Hordern,
2014) whilst attaining multi-residue enantiomeric separa-
tions would be advantageous. Until their development, the
use of comparatively fast achiral UPLC methods supported
with chiral separations to determine enantiomeric fraction for
as many chemicals as possible is suggested. Targeted UPLC
methods are capable of the simultaneous determination of up
to 100 ECs in various environmental matrices at relatively
short analysis times (~10 min) (Gracia-Lor et al., 2011; Lopez-
Serna et al., 2011; Gros et al., 2012). Ideally, these multi-
residue methods used for the analysis of ECs should be dy-
namic such that they can perform non-targeted (qualitative)
screening whilst undertaking targeted (quantitative) de-
terminations. The use of high resolution mass spectrometers
such as QTOF or Orbitrap technology which can undertake
both targeted and non-targeted screening and allow for
retrospective analysis is beneficial (Radjenovic et al., 2009b).
Such technology enables chemicals not originally included in
targeted screening but identified as of interest, to be easily
added for subsequent quantitative determination. The suc-
cess of non-targeted screening is reliant on good chromato-
graphic separation. Therefore the chromatography method
should be optimised for the separation of a broad range of
target ECs representing extremities of physicochemical
composition (hydrophobicity, molecular weight etc). Coupled
with screening in both negative and positive ionisationmodes
will help identify unknown chemicals of notable concentra-
tion. However, non-targeted screening has several limitations
as the chemistry of the ECs in question is unknown. Therefore
they may not be recovered during sample preparation or maynot be ionised during analysis. Chemical analysis also needs
to be supported with novel bioanalytical techniques (e.g.,
metabolomics). Using a metabolomics approach can yield in-
formation on organism function and health at the molecular
level (Bundy et al., 2009). Such information would otherwise
be missed by traditional toxicological tests which rely on
endpoints such as growth, death and reproduction for a
limited number of indicator species. Long term multi-
generational studies at different trophic levels which can
simulate environmental conditions and EC concentrations are
needed. This would help establish the ecological impact of
observed EC concentrations within the environment.4.3. Conclusions and future outlook
It is anticipated that environmental legislation will be
widened to cover a range of municipal derived ECs. However,
sound knowledge of their fate during wastewater treatment
and within the environment is currently lacking. Due to the
limitations of previously used sampling methods, reported
removals of ECs by WwTWs have uncertainties. Therefore,
removal performance of different WwTW process types at
various operational conditions needs re-evaluated with suit-
able sampling protocols. This will help establish steps
required for EC amelioration. The growing trend of improving
sustainability and reducing energy demand of wastewater
treatment will see an increase in the application of novel
treatment methods. For example, algae ponds for secondary
effluent polishing are a promising treatment method which
can indirectly produce energy through the production of
biogas. However, there are very few studies which have
monitored their performance for EC removal (De Godos et al.,
2012). Further studies of these process types are needed to
determine fate and removal of ECs during treatment, consid-
ering their likely implementation into the conventional
WwTW flow sheet. Environmental monitoring must also now
apply a holistic approach. This involves determining fate and
impact of ECs across their complete life cycle which includes
the terrestrial environment. For example, measuring biosolids
and amended soils for their occurrence is needed as well as
supporting analysis. Detailed case studies of amended soils in
field conditions which investigate leaching and runoff, impact
to surrounding surface water quality, in soil degradation,
toxicity to terrestrial organisms and the potential uptake by
plants and entry into the human food chain are needed. A
similar approach can be taken for monitoring other contam-
inated environmental compartments such as river sediments.
Finally, the combined use of chemical and biological analysis
to better assess environmental impact from ECs will enable
the revision and development of more accurate environ-
mental risk assessment.Acknowledgements
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